Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mink Therapeutics Inc
(NQ:
INKT
)
0.9275
+0.0563 (+6.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
32,366
Open
0.9000
Bid (Size)
0.9002 (1)
Ask (Size)
0.9748 (6)
Prev. Close
0.8712
Today's Range
0.8812 - 0.9300
52wk Range
0.7500 - 3.340
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Monday's Intraday Session
April 08, 2024
Via
Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Performance
YTD
-14.91%
-14.91%
1 Month
+1.92%
+1.92%
3 Month
+9.97%
+9.97%
6 Month
+1.87%
+1.87%
1 Year
-50.66%
-50.66%
More News
Read More
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 05, 2024
Via
Benzinga
Earnings Outlook For MiNK Therapeutics
March 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 05, 2024
Via
Benzinga
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
March 21, 2024
Via
InvestorPlace
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 21, 2024
March 21, 2024
Via
Benzinga
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
February 06, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
January 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
December 20, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
November 09, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
November 03, 2023
Via
Benzinga
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
November 03, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
October 30, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
Sacks Parente Golf And 3 Other Stocks Under $2 Insiders Are Buying
October 17, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
October 09, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 04, 2023
Via
Benzinga
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
September 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
August 24, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.